Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pyxis Oncology (PYXS) EBIT (2024 - 2025)

Historic EBIT for Pyxis Oncology (PYXS) over the last 2 years, with Q3 2025 value amounting to -$23.5 million.

  • Pyxis Oncology's EBIT rose 123.35% to -$23.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$106.2 million, marking a year-over-year change of. This contributed to the annual value of -$89.5 million for FY2024, which is 883.74% down from last year.
  • Per Pyxis Oncology's latest filing, its EBIT stood at -$23.5 million for Q3 2025, which was up 123.35% from -$19.8 million recorded in Q2 2025.
  • Pyxis Oncology's 5-year EBIT high stood at -$5.6 million for Q1 2024, and its period low was -$40.1 million during Q4 2024.